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Abstract We have expressed and purified a protein fragment
from Entamoeba histolytica. It catalyses transhydrogenation
between analogues of NAD(H) and NADP(H). The character-
istics of this reaction resemble those of the reaction catalysed by
a complex of the NAD(H)- and NADP(H)-binding subunits of
proton-translocating transhydrogenases from bacteria and mam-
mals. It is concluded that the complete En. histolytica protein,
which, along with similar proteins from other protozoan
parasites, has an unusual subunit organisation, is also a
proton-translocating transhydrogenase. The function of the
transhydrogenase, thought to be located in organelles which do
not have the enzymes of oxidative phosphorylation, is not
clear. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Transhydrogenase couples the direct transfer of hydride-ion
equivalents between the NC4A-position of NAD(H) and the
NC4B-position of NADP(H) to the translocation of protons
across a membrane:
NADHNADP HoutINAD NADPHHin 1
The enzyme has been isolated and puri¢ed from the cyto-
plasmic membranes of bacteria and the inner membranes of
mammalian mitochondria, and studied in detail (for reviews
see [1,2]). Transhydrogenase has three components; dI, which
has the binding site for NAD(H), and dIII, which has the
binding site for NADP(H), protrude from the membrane,
and dII spans the membrane. High-resolution structures of
isolated dI [3] and dIII [1,4^6] were recently presented.
Genome sequences indicate that transhydrogenase is widely
distributed in animal cells and many bacteria. It is absent
from some bacteria, from Saccharomyces cerevisiae and prob-
ably from higher plants, though it is present in cyanobacteria
and the green alga, Acetabulum acetabularia. In mammals,
transhydrogenase has a single polypeptide, which runs dI^
dII^dIII, N-terminus to C-terminus (Fig. 1). The intact mam-
malian protein is probably homodimeric [7,8]. In bacteria,
gene sequences show that the dII component is always sepa-
rated into dIIa and dIIb. Additionally, in some bacteria, dI is
separated from dIIa. Thus, in Escherichia coli, Salmonella
typhimurium and Haemophilus in£uenzae, for example, there
are two polypeptides, PntA or K (comprising dI^dIIa) and
PntB or L (comprising dIIb^dIII), whereas in Rhodospirillum
rubrum, Mycobacterium tuberculosis and Bordetella pertussis
and others, there are three polypeptides: PntAA (dI), PntAB
(dIIa) and PntB (dIIb^dIII). Intact E. coli transhydrogenase is
an K2L2 dimer [9], but the oligomeric state of other bacterial
species is not known.
Putative transhydrogenases have been identi¢ed from gene
sequences of some protozoan parasites (Entamoeba histolytica
[10,11], Eimeria tenella [12,13], Plasmodium falciparum) but
they are unusual (Fig. 1). The predicted order of components
in the single polypeptide is dIIb^dIII^dI^dIIa. Thus, the N-
terminus of the protein corresponds to the N-terminus of the
bacterial L polypeptide (PntB). An extra segment (38 amino
acid residues in both Ei. tenella and En. histolytica) is pre-
dicted between dIII and dI and might simply serve as a linker.
The location of the putative transhydrogenase in these organ-
isms also raises interesting questions. Their protein pre-se-
quences are either grossly modi¢ed from the characteristic
mitochondrial pre-sequence (En. histolytica), or they are en-
tirely lacking (Ei. tenella). Immunochemical experiments sug-
gest that the Ei. tenella dIIb^dIII^dI^dIIa protein is located,
not in the mitochondria, but in ‘refractile bodies’ of unknown
function [13]. In En. histolytica (which does not possess mi-
tochondria), comparison of the protein pre-sequence with that
of Hsp60 suggests that the dIIb^dIII^dI^dIIa protein is asso-
ciated with ‘mitosomes’ or ‘cryptons’, small organelles which
number only about one per cell [14^17]. Although the mito-
somes/cryptons are mitochondrially derived, they are thought
to lack the enzymes of oxidative phosphorylation.
Transhydrogenation activity in lysing, intact cells of En.
histolytica was reported [18] but the protein(s) responsible
for the activity were not characterised. In the present work,
we have isolated DNA coding for the putative dIII^linker^dI
region of En. histolytica transhydrogenase (henceforth called
ehdIII^dI), and expressed and puri¢ed the protein. Its cata-
lytic properties closely resemble those of complexes formed
from mixtures of isolated dI and isolated dIII from transhy-
drogenases of bacteria and mammalian mitochondria [19^21].
This result indicates that the complete enzyme is probably a
transhydrogenase with properties typical of those found in
other species.
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2. Materials and methods
DNA coding for ehdIII^dI (from Met236^Lys931 of the complete
protein) was isolated by polymerase chain reaction (PCR) with a
construct supplied by Dr. C.G. Clark, of the London School of Hy-
giene and Tropical Medicine, as target. Primers were synthesised by
Alta Bioscience. The 44-base sense-primer, constructed from nucleo-
tide residues 975^1006, incorporated a BspHI restriction site. The 40-
base anti-sense-primer, constructed from nucleotide residues 2765^
2792, incorporated a stop codon (at position 2790^2792) and a Bam-
HI restriction site. The PCR product was cloned into pPCR-Script
using the pPCR-Script Amp SK(+) cloning kit (Stratagene). The
BspHI and BamHI fragment was then subcloned into the expression
vector pET21d (Novagen), to give pCJW3, which was transformed
into E. coli BL21(DE3). Plasmid preparations from selected clones
were sequenced using an Applied Biosystems 373A.
Expression of ehdIII^dI was induced by addition of 1 mM isopro-
pyl L-D-thiogalactoside to mid-log phase cells grown at 25‡C in
NZCYM media [22]. Cells were harvested 14 h post-induction by
centrifugation, washed in 50 mM Tris^HCl pH 8.0, 1 mM EDTA,
2 mM dithiothreitol (TED bu¡er) and stored at 320‡C. The cells were
thawed, resuspended in TED bu¡er supplemented with 0.5 mM phe-
nylmethylsulphonyl £uoride and 100 WM NADP, and disrupted by
sonication. Soluble cell extract, obtained by centrifugation at
105 000Ug for 120 min, was applied to a 5U30 cm column of Q-
Sepharose Fast Flow (Pharmacia Biotech) equilibrated with 20 mM
Tris^HCl pH 8.0, 2 mM dithiothreitol, 4 WM NADP (bu¡er A) and
the column was developed with a gradient of 0^0.5 M NaCl. Active
fractions were pooled, dialysed (1:15) in bu¡er A supplemented with
10% glycerol for 2 h, and then brought to 10% saturation with am-
monium sulphate and incubated overnight at 4‡C. Precipitate was
removed by ¢ltration, and the protein solution was applied to a
2.6U18 cm column of Phenyl-Sepharose HP (Pharmacia Biotech)
equilibrated in bu¡er A supplemented with 10%-saturated ammonium
sulphate. The column was developed with a reverse gradient of am-
monium sulphate (10 to 0% saturation) followed by a 0^20% glycerol
gradient. Recombinant ehdIII^dI was eluted in the glycerol wash.
Active fractions were pooled, concentrated to V3 ml (Vivascience
centrifugal ¢lters, 10 kDa cut-o¡) and subjected to a ¢nal puri¢cation
step on a 2.6U62 cm column of Hiload Superdex 200 (Pharmacia
Biotech) equilibrated in bu¡er A supplemented with 150 mM NaCl
and 5% glycerol. The protein was subsequently stored in 25% glycerol
at 380‡C in 2 ml thin-walled cryovials (Nalgene). SDS^PAGE was
performed using a discontinuous bu¡er system as described [23]. Pro-
tein concentration was measured by the microtannin assay [24] with
bovine serum albumin as standard.
Reverse and cyclic transhydrogenase activities were measured spec-
trophotometrically by following the reduction of acetyl pyridine nic-
otinamide dinucleotide (oxidised form) (AcPdAD) at 375 nm, 25‡C,
using a Perkin Elmer Lambda 16 spectrophotometer, and an absor-
bance coe⁄cient of 6.10 mM31 cm31 [25]. Forward transhydrogena-
tion rates were measured by following the reduction of thio-NADP
at 395 nm, using an absorbance coe⁄cient of 11.3 mM31 cm31 [26].
The reaction bu¡er was 50 mM MOPS^KOH, pH 7.2, 50 mM KCl, 2
mM MgCl2. For pH-dependence measurements the bu¡er was 20 mM
MES, 20 mM MOPS, 20 mM HEPES, 20 mM CHES, 50 mM KCl
and 2 mM MgCl2, set to an appropriate pH with HCl or NaOH.
Prior to all experiments, the stored protein was thawed on ice, con-
centrated in centrifugal ¢lters (10 kDa cut-o¡) and washed with re-
action bu¡er supplemented with 2 mM DTT and 4 WM NADP.
3. Results
There are 10 di¡erences between the two published nucleo-
tide sequences of the gene coding for the putative dIIb^dIII^
dI^dIIa transhydrogenase of En. histolytica [10,11]. In our
determinations, the sequences of the DNA insert coding for
dIII^dI in pCJW3 (this work), and of the parent genomic
clone, were identical to that in [11], except for a single base
change to an A at position 2567; this base is an A also in [10].
Induction of cells of E. coli BL21(DE3) bearing pCJW3
with isopropyl L-D-thiogalactoside led to the expression of a
protein, whose Mr of 66 kDa on SDS^PAGE corresponds to
that of ehdIII^dI. The protein was puri¢ed by column chro-
matography. Typically, V100 mg of the protein (s 90% pure
according to staining intensity on SDS^PAGE) were recov-
ered from 3.2 l of E. coli culture. The puri¢ed protein eluted
with an MrW155 kDa during non-denaturing gel-¢ltration
chromatography; the predicted Mr of the monomer is 65.8
kDa.
After dialysis of the puri¢ed protein (87 WM in bu¡er con-
taining 4 WM NADP, see Section 2) against 1000 volumes of
20 mM Tris^HCl, pH 8.0 and 2 mM dithiothreitol, to remove
excess and weakly associated nucleotide, it remained fully ac-
tive (see below). Subsequent analysis (see [20]) indicated that
the dialysed material retained 0.54 mol NADP per mol pro-
tein; there was no bound NADPH, NAD or NADH. Under
equivalent conditions, the isolated dIII component of R. ru-
brum [20], E. coli [21] and human [27] transhydrogenases also
retain tightly bound nucleotide.
The catalytic properties of the puri¢ed, tethered ehdIII^dI
protein were generally very similar to those of the complex
formed from a mixture of the isolated dI and dIII components
of R. rubrum [20] or E. coli [21] transhydrogenase, or of var-
ious hybrids of the bacterial and mammalian enzymes [27,28].
Thus, puri¢ed ehdIII^dI catalysed both ‘reverse transhydroge-
nation’ (the reduction of the NAD analogue, AcPdAD, by
NADPH, Fig. 2), and ‘forward transhydrogenation’ (the re-
duction of thio-NADP by NADH, data not shown), only at
very low rates. However, the protein catalysed ‘cyclic trans-
hydrogenation’ (the reduction of AcPdAD by NADH in the
presence of NADP, Fig. 2) at a very high rate. The rapid
rate of this reaction, which involves the alternate reduction of
NADP by NADH, and the oxidation of NADPH by
AcPdAD [29], shows that (a) NAD(H) and AcPdAD(H)
binding and release, and (b) the two hydride transfer reactions
on the protein (NADHCNADP and NADPHC
AcPdAD), are both relatively fast. Cyclic transhydrogena-
tion proceeds rapidly when NADP and NADPH remain
bound to the protein [29]. It is therefore concluded that the
low rates of forward and reverse transhydrogenation by
ehdIII^dI (similar to the reactions catalysed by R. rubrum
dI:dIII complexes) are a consequence of slow release of prod-
uct NADPH and NADP, respectively. Note that the sub-
strate inhibition of the cyclic reaction, observed at high con-
centrations of NADH (Fig. 2), is probably a consequence of
competition between NADH and AcPdAD for the same
binding site [30].
Fig. 1. Subunit organisation of transhydrogenases. See text.
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The pH dependence of reverse transhydrogenation by eh-
dIII^dI resembles that described in detail for the dI:dIII com-
plex of R. rubrum transhydrogenase (Fig. 3); the increase in
rate at low pH is attributed to acceleration of NADP release
due to protonation of dIII (J.D. Venning and D. Rodrigues,
personal communication). The pH dependence of the cyclic
reaction (Fig. 3), thought to be dominated by the protonation
state of dI, reveals a pKaW7.2, intermediate between those of
the R. rubrum [31] and E. coli [21,28] dI:dIII complexes.
4. Discussion
The results presented above show that the tethered dIII^dI
component of the dIIb^dIII^dI^dIIa protein from En. histo-
lytica has transhydrogenase activity. The relative rates of the
reverse and cyclic reactions catalysed by ehdIII^dI prove that
the hydride transfer steps on the protein are fast, but that the
rates of NADP and NADPH release from their binding sites
are slow. For the well-characterised transhydrogenases from
bacteria and animal mitochondria, it is established that inter-
actions with the membrane-spanning dII accelerate NADP
and NADPH release from dIII, and that this is important in
the coupling to proton translocation [1]. Because the charac-
teristics of the proteins are so similar, it is likely that the same
situation applies to the En. histolytica enzyme. Thus, the dIIb^
dIII^dI^dIIa proteins of the protozoan parasites are very
probably proton-translocating transhydrogenases, as pre-
dicted [10,11].
This conclusion re-focuses on the question as to the func-
tion of transhydrogenase in this group of organisms. The
primary issue is to identify the protein(s) that operate in series
with transhydrogenase in the expected chemiosmotic proton
circuit. En. histolytica grows by fermentation [32]. It lacks
some of the enzymes of the TCA cycle [32,33], and is reported
not to have cytochromes [32,34]. However, the dIIb^dIII^dI^
dIIa transhydrogenase is thought to be located in mitosomes
(or cryptons) [14,15], which are mitochondrially derived or-
ganelles, present only in small numbers in the cell, and it is
doubtful if earlier analyses would have been sensitive enough
to detect small quantities of redox components in such a mi-
nor cellular component. Thus, it remains entirely possible that
the mitosomes do possess a proton-pumping electron trans-
port chain (not necessarily with O2 as the terminal electron
acceptor), that would drive transhydrogenation. The existence
of F-type ATPase has not been reported in En. histolytica,
although there is evidence for a V-type ATPase [35], the lo-
cation of which is unknown. The relatively small amount of
membrane associated with the mitosome make it very unlikely
that transhydrogenase will play a signi¢cant role in the central
metabolic pathways of the organism (contrast [32]). Thus,
unless it is unusually enriched within the organelle membrane,
Fig. 3. The pH dependence of transhydrogenation catalysed by the
ehdIII^dI protein. Cyclic transhydrogenation (A) was carried out in
the presence of 630 nM ehdIII^dI, 21 WM NADP, 57 WM NADH
and 193 WM AcPdAD. For reverse transhydrogenation (B), 1.26
WM protein was present, with 51 WM NADPH and 193 WM
AcPdAD. See Section 2.
Fig. 2. Transhydrogenation reactions catalysed by ehdIII^dI. For
cyclic transhydrogenase activity (A) the concentrations of ehdIII^dI,
NADP and AcPdAD were 1, 21 and 219 WM, respectively. The
concentration of NADH was varied as indicated. For reverse trans-
hydrogenase activity (B) the protein concentration was 2 WM and
the NADPH concentration was 25 WM. The concentration of
AcPdAD was varied as indicated. See Section 2.
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the enzyme will not have the catalytic capacity to shift large
amounts of reducing power between cytoplasmic NAD(H)
and NADP(H). More likely, the transhydrogenase, with its
catalytic site facing the ‘matrix’ of the mitosome (as in its
mitochondrial progenitor), will be responsible for controlling
the redox state of the nicotinamide nucleotide pools within the
organelle, but for what purpose, remains to be established. A
biochemical examination of the mitosome is awaited to fur-
ther an understanding of this problem.
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